Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Opinion
Video
Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing
Key Takeaways
- Strategic sequencing of bispecific antibodies and CAR T-cell therapy is crucial for optimizing outcomes in RRMM treatment.
- Operational challenges include coordinating multidisciplinary teams, managing toxicities, and ensuring timely access to therapies.
Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.
Video content above is prompted by the following
- How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
- What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?
Related Videos
Related Content
